Past Issue

Volume 6, Number 4, Jan-Mar 2013, Pages: 266-271

Microdose GnRH Agonist Flare-Up versus Ultrashort GnRH Agonist Combined with Fixed GnRH Antagonist in Poor Responders of Assisted Reproductive Techniques Cycles


Maryam Eftekhar, M.D., 1, Farnaz Mohammadian, M.D., 1, 2, Fariba Yousefnejad, M.D., 1, Parisa Khani, M.D., 3, *,
Department of Obstetrics and Gynecology, Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Department of Obstetrics and Gynecology, Zanjan University of Medical Sciences, Zanjan, Iran
Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
* Corresponding Address: P.O.Box: 89195999 Research and Clinical Center for Infertility Shahid Sadoughi University of Medical Sciences YazdIran Email: pkhani55@gmail.com

Abstract

Background:

This study compares the microdose flare-up protocol to the ultrashort gonadotropinreleasing hormone (GnRH) agonist flare combined with the fixed multidose GnRH antagonist protocol in poor responders undergoing ovarian stimulation.

Materials and Methods:

In this randomized clinical trial, 120 women who were candidates for assisted reproductive techniques (ART) and had histories of one or more failed in vitro fertilization (IVF) cycles with three or fewer retrieved oocytes were prospectively randomized into two groups. Group I (60 patients) received the microdose flare-up regimen and group II (60 patients) received the ultrashort GnRH agonist combined with fixed GnRH antagonist.

Results:

There were no significant differences between the groups in the number of used gonadotropin ampoules (p=0.591), duration of stimulation (p=0.610), number of retrieved oocytes (p=0.802), fertilization rate (p=0.456), and the number of transferred embryos (p=0.954). The clinical pregnancy rates were statistically similar in group I (10%) compared with group II (13.3%, p=0.389).

Conclusion:

According to our results, there is no significant difference between these protocols for improving the ART outcome in poor responders. Additional prospective, randomized studies with more patients is necessary to determine the best protocol (Registration Number: IRCT201105096420N1).